Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3CNS 1

Conditions

Brain Neoplasms 2Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Breast Neoplasms 1

Interventions

Trastuzumab 20Radiosurgery 15Magnetic Resonance Spectroscopy 15Capecitabine 14Lapatinib 12Radiotherapy 11Specimen Handling 10Cyclophosphamide 9trastuzumab deruxtecan 8Temozolomide 8Docetaxel 8Paclitaxel 7Gemcitabine 6Cisplatin 6sacituzumab govitecan 5Vinorelbine 5Therapeutics 5Spinal Puncture 5Flow Cytometry 5tucatinib 4pembrolizumab 4paclitaxel-Angiopep-2 conjugate 4eribulin 4Methotrexate 4Irinotecan 4Fluorodeoxyglucose F18 4Dexamethasone 4Bevacizumab 4temsirolimus 3pyrotinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × sagopilone × CNS × Clear all
NCT00496379 2013-03-14

ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

Dana-Farber Cancer Institute

Phase 2 Terminated
15 enrolled 10 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡